(1) Background: Bone metastasis is among diseases that frequently appear in breast, lung and prostate cancer; the most popular imaging method of screening in metastasis is bone scintigraphy and presents very high sensitivity (95%).
Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs). To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC.
Despite longer survival with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1), metastatic urothelial carcinoma remains lethal. There is an unmet need to further improve the efficacy of these agents.
The aim was to evaluate dosimetric uncertainties of a mixed beam approach for patients with high-risk prostate cancer (PCa). The treatment consists of a carbon ion radiotherapy (CIRT) boost followed by whole-pelvis intensity-modulated RT (IMRT).
The objective of this work was to assess the value of 68Ga-DOTAGA-(3-iodo-y)fk(Sub-KuE) positron emission tomography (68Ga-PSMA-I/T PET-CT) and multiparametric magnetic resonance imaging (mp-MRI) for preoperative staging in prostate cancer (PCa) patients who underwent radical prostatectomy (RP) by validating with postoperative histopathology data.
(UroToday.com) In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled “Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?”, Dr. Karen Autio from the Memorial Sloan […]
(UroToday.com) In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled “Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer”, Dr. Alicia Morgans from Northwestern University […]
(UroToday.com) The 2020 American Society of Clinical Oncologists (ASCO) virtual education program featured a roundtable discussion with several health policy leaders regarding ethical issues that have been raised in oncology during the COVID-19 pandemic. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
(UroToday.com) The 2020 American Society of Clinical Oncologists (ASCO) virtual education program featured a session on the evolution of renal cell carcinoma (RCC) treatment, including a presentation by Dr. Jaleh Fallah from the Cleveland Clinic discussing sequencing and combining targeted and immunotherapy. Over the last couple of years, trials have utilized combination therapy to continue improving […]
(UroToday.com) At the ASCO 2020 virtual education program, Janice Dutcher, MD, discussed the beginnings of immunotherapy for renal cell carcinoma (RCC) as part of the evolution of RCC treatment session of talks. Cytokines are endogenous substances within the immune system and are responsible for cell signaling, as well as induction or inhibition of various cell regulatory […]
